Katya

Ethinylestradiol and Gestodene, the active ingredients in Katya, are a combined oral contraceptive presented as a tablet for oral use. The formulation works to prevent pregnancy by inhibiting ovulation, altering cervical mucus, and modifying the endometrium, and is indicated for women of reproductive age seeking reliable hormonal contraception.

GNH USA supplies Katya as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Katya, a combined oral contraceptive, is used within the hormonal contraception pathway to prevent pregnancy.

Prevention of pregnancy: provides effective contraception for women of childbearing potential. Regulation of menstrual cycle: helps achieve more predictable bleeding patterns. Treatment of moderate acne: reduces androgen‑driven skin lesions in eligible patients.

Katya may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: transient swelling or discomfort. - Spotting between periods: irregular light bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein clot formation. - Stroke: cerebrovascular accident, especially in high‑risk individuals. - Liver tumor: benign hepatic adenoma development.

Before prescribing Katya, clinicians should consider several safety aspects.

Assess cardiovascular risk: evaluate history of thrombosis, hypertension, smoking. Avoid use in pregnancy: discontinue immediately if pregnancy is confirmed. Monitor hepatic function: check liver enzymes in patients with liver disease. Review concomitant medications: identify drugs that may alter estrogen metabolism. Counsel on smoking cessation: especially for women over 35 years old. Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and light.

Katya can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely): - Other estrogen‑containing products: may increase overall estrogen exposure. - Certain antiepileptics (e.g., phenytoin, phenobarbital): may modestly lower effectiveness. - Grapefruit juice: can affect metabolism of gestodene, requiring monitoring.